First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

Study Name
	First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
ClinicalTrials.gov Identifier (if applicable)
	NCT04526106
Clinical Trial Category (check all that apply)
	First Line Therapy Beyond First Line Therapy Targeted Therapy
Study Center
Institution Name
	Please see clinicaltrials.gov
Country
	United States
Study Contacts
Principal Investigator
	Please see clinicaltrials.gov
P.I. Phone
	(339) 230-7475
P.I. Email
	ClinicalTrials@relaytx.com
Study Coordinator
	Please see clinicaltrials.gov
Study Coordinator Phone
	(339) 230-7475
Study Coordinator Email
	ClinicalTrials@relaytx.com
OVERVIEW – in layman’s terms (150 words max)
	This clinical trial is studying the safety and effectiveness of an investigational drug for patients with Cholangiocarcinoma and other solid tumors that meet eligibility requirements. This investigational drug is a highly selective Fibroblast Growth Factor Receptor 2 (FGFR2) inhibitor. Please refer to Clinicaltrials.gov for more information.
Enrollment
	Ongoing
Study Start Date
	09/01/2020
Estimated Completion Date
	10/01/2024